Gastroenterology
Volume 134, Issue 1 , Pages 166-178, January 2008

PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

  • Guillaume Dalmasso
  • ,
  • Laetitia Charrier–Hisamuddin

      Affiliations

    • Laetitia Charrier-Hisamuddin is a recipient of a research career development award from the Crohn’s and Colitis Foundation of America and Yutao Yan is a recipient of a research fellowship award from the Crohn’s and Colitis Foundation of America.
  • ,
  • Hang Thi Thu Nguyen
  • ,
  • Yutao Yan
  • ,
  • Shanthi Sitaraman
  • ,
  • Didier Merlin

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Didier Merlin, PhD, Department of Medicine, Division of Digestive Diseases, Emory University, 615 Michael Street, Atlanta, Georgia 30322. fax: (404) 727-5767.

Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, Georgia

Received 18 May 2007; accepted 4 October 2007. published online 19 October 2007.

Background & Aims: KPV is a tripeptide (Lys-Pro-Val), which possesses anti-inflammatory properties; however, its mechanisms of action still remain unknown. PepT1 is a di/tripeptide transporter normally expressed in the small intestine and induced in colon during inflammatory bowel disease (IBD). The aim of this study was to 1) investigate whether the KPV anti-inflammatory effect is PepT1-mediated in intestinal epithelian and immune cells, and 2) examine the anti-inflammatory effects in two models of mice colitis. Methods: Human intestinal epithelial cells Caco2-BBE, HT29-Cl.19A, and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines in the present or absence of KPV. KPV anti-inflammatory effect was assessed using a NF-κB luciferase gene reporter, Western blot, real-time RT-PCR and ELISA. Uptake experiments were performed using cold KPV as a competitor for PepT1 radiolabelled substrate or using [3H]KPV to determine kinetic characteristics of KPV uptake. Anti-inflammatory effect of KPV was also investigated in DSS- and TNBS-induced colitis in mice. KPV was added to drinking water and inflammation was assessed at the histologic level and by proinflammatory cytokine mRNA expression. Results: Nanomolar concentrations of KPV inhibit the activation of NF-κB and MAP kinase inflammatory signaling pathways, and reduce pro-inflammatory cytokine secretion. We found that KPV acts via PepT1 expressed in immune and intestinal epithelial cells. Furthermore, oral administration of KPV reduces the incidence of DSS- and TNBS-induced colitis indicated by a decrease in pro-inflammatory cytokine expression. Conclusions: This study indicates tht KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.

Abbreviations used in this paper: cAMPi, intracellular cyclic adenosine monophosphate, DSS, dextran sodium sulfate, ELISA, enzyme-linked immunosorbent assay, Gly-Leu, glycine-leucine, Gly-Sar, glycine-sarcosine, IEC, intestinal epithelial cell, IL, interleukin, KPV, Lys-Pro-Val, MAPK, mitogen-activated protein kinase, MCR, melanocortin receptor, MPO, myeloperoxidase, α−MSH, α-melanocyte–stimulating hormone, NF-κB, nuclear factor-κB, PepT1, H+-coupled oligopeptide transporter 1, RT-PCR, reverse-transcription polymerase chain reaction, TNF-α, tumor necrosis factor-α

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the National Institutes of Health of Diabetes and Digestive and Kidney Diseases by grants R24-DK-064399 (center grant), RO1-DK-061941, RO1-DK-071594 (D.M.), and RO1-DK55850 (S.S.).

PII: S0016-5085(07)01852-5

doi:10.1053/j.gastro.2007.10.026

Gastroenterology
Volume 134, Issue 1 , Pages 166-178, January 2008